2,101 results on '"Amyloid Neuropathies, Familial"'
Search Results
2. Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
3. Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia (LOCUS)
4. MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
5. Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045. (TRAMA)
6. APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
7. New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
8. hATTR Polyneuropathy in Russia (PRIMER)
9. A Non-interventional Cohort Safety Study of Patients With hATTR-PN
10. Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis (MED-hATTR)
11. Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia (TETRAMER)
12. Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
13. HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
14. Phenotyping and Characterization of wtATTR-CM (TRACE 1)
15. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
16. Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology (TTRACK)
17. Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
18. A Clinical Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Patients With hATTR-PN
19. Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF (TTRinHFpEF)
20. Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population (CarPoS)
21. TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects (TRAMmoniTTR)
22. Early and Systematic Screening in Chronic Neuropathy (TTR-FAP)
23. Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
24. This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
25. Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
26. Transthyretin Amyloidosis Outcome Survey (THAOS) (THAOS)
27. Exploring Biomarkers in Hereditary Transthyretin Amyloidosis (ELBA)
28. Renal tubular acidosis in hereditary transthyretin amyloidosis (ATTRv)
29. The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis. (AMYLOIDOZA)
30. Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP) (BioTRAP)
31. Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
32. Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients (TTR-SNC)
33. Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology (PRE-TRANS)
34. Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
35. Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition
36. Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
37. Systemische Amyloidoseformen mit kardialer Manifestation.
38. Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis (ITALY)
39. Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
40. The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
41. Characterization of the F8 gene: a silver lining in a dark cloud.
42. Nuclear imaging techniques for cardiac amyloidosis.
43. ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
44. Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center
45. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system.
46. Ultrasensitive Proteomics of Trace Cardiac Tissues with Anchor-Nanoparticles.
47. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
48. Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany.
49. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis.
50. The Effect of Diflunisal on Familial Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.